trial

Conversion to Antipsychotic Monotherapy

NCTId NCT01368458
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Terminated
Enrollment 24 (estimated)
Sponsored by Nathan Kline Institute for Psychiatric Research
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Terminated
Enrollment
24 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Single
Start
2007-12
Primary completion
—
Eligibility
ALL · 18 Years · 75 Years

Interventions & indications

Drugs
Conversion to Antipsychotic Monotherapy

Sponsors

Nathan Kline Institute for Psychiatric ResearchLead Sponsor

Investigators

1
Joshua T Kantrowitz, MDPrincipal Investigator

Sites

0 total

Facts & assertions

3 sourced
Enrollment
24
Phase
NA
Status
TERMINATED
relationships
The graph out of here
drug
Conversion to Antipsychotic Monotherapy
drug
lead_sponsor
Nathan Kline Institute for Psychiatric Research
company
indication
Schizophrenia
indication
Schizoaffective Disorder
indication
Schizophrenia
indication
investigator
Joshua T Kantrowitz, MD
person